Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:45:46 EDT Sat 18 Jul 2026
Enter Symbol
or Name
USA
CA



Q:FBIO - FORTRESS BIOTECH INC - https://fortressbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FBIO - Q0.13.35·5.833.43.36-0.06-1.8304.09302,0793.35  3.48  3.304.53  1.7718:34:50May 1915 min RT 2¢

Recent Trades - Last 10 of 2079
Time ETExPriceChangeVolume
18:34:50Q3.38-0.0495
18:26:52Q3.40-0.028
18:02:09Q3.40-0.02190
17:56:36Q3.40-0.02310
17:06:37Q3.41-0.015
16:10:05Q3.36-0.061
16:10:04Q3.36-0.061
16:10:04Q3.36-0.061
16:04:52Q3.36-0.061
16:04:25Q3.36-0.061

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-19 16:45U:FBIONews ReleaseJourney Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
2026-05-18 08:30U:FBIONews ReleaseFortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
2026-05-14 16:10U:FBIONews ReleaseFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-13 16:01U:FBIONews ReleaseJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-06 16:01U:FBIONews ReleaseJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
2026-05-04 08:30U:FBIONews ReleaseFortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
2026-04-21 08:30U:FBIONews ReleaseJourney Medical Corporation Secures Contract with Third Major GPO for Emrosi(TM)
2026-03-31 16:05U:FBIONews ReleaseFortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
2026-03-30 16:05U:FBIONews ReleaseFortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
2026-03-25 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
2026-03-18 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
2026-02-23 09:24U:FBIONews ReleaseUPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2026-02-23 08:30U:FBIONews ReleaseFortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2026-02-23 08:00U:FBIONews ReleaseAvenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
2026-01-13 07:45U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO(TM) (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
2025-12-15 08:00U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
2025-12-10 08:30U:FBIONews ReleaseJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi(TM) (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
2025-11-14 08:30U:FBIONews ReleaseFortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
2025-11-12 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
2025-11-06 07:00U:FBIONews ReleaseAvenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics